Institutul Regional De Oncologie Iasi
- Address
- Strada G-Ral Berthelot 2-4, 700483 Iasi, Romania
Multiple Myeloma Maintenance Therapy
The research team at Institutul Regional De Oncologie Iasi is evaluating new maintenance strategies for patients with newly diagnosed multiple myeloma after autologous stem cell transplant, aiming to improve progression‑free survival.
- Comparison of iberdomide versus lenalidomide
- Assessment of long‑term safety
- Impact on quality of life
This work seeks to identify a more effective oral agent that can sustain remission and enhance patient outcomes in the post‑transplant setting.
Head and Neck Cancer Immunotherapy
In the field of Head and Neck Squamous Cell Carcinoma, investigators are testing novel immunotherapy combinations against a checkpoint inhibitor to determine antitumor activity in PD‑L1 positive recurrent or metastatic disease.
- Combination immunotherapy regimens
- Biomarker‑driven patient selection
- Evaluation of response rates
The goal is to expand first‑line treatment options and improve survival for patients with advanced disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institutul Regional De Oncologie Iasi
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE | Incyte Corp. | Phase II | Not Recruiting | Nov 2023 | Feb 2026 |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-09-29 | 2023-09-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.